Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amyloidosis: a clinico-pathophysiological synopsis.

Gideon M Hirschfield1

  • 1NHS National Amyloidosis Centre, Royal Free Hospital, London, UK. g.hirschfield@rfc.ucl.ac.uk

Seminars in Cell & Developmental Biology
|March 24, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Letter: Assessing Pruritus Efficacy With Peroxisome Proliferator-Activated Receptor Agonists in Primary Biliary Cholangitis Must Include Grading the Strength of Trial Evidence.

Alimentary pharmacology & therapeutics·2026
Same author

Can we cure primary biliary cholangitis?

Current opinion in immunology·2026
Same author

Reply: Fracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis.

Hepatology communications·2026
Same author

Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial.

Alimentary pharmacology & therapeutics·2026
Same author

Primary Biliary Cholangitis and Prognostic Models-Reply.

JAMA·2026
Same author

The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view.

Nature reviews. Gastroenterology & hepatology·2026

Amyloidosis involves protein misfolding and extracellular fibril deposition, impairing tissue function. Advances in understanding amyloidogenesis improve diagnosis and treatment for these diverse diseases.

Area of Science:

  • Biochemistry
  • Pathology
  • Genetics

Background:

  • Amyloidosis comprises diseases characterized by misfolded proteins forming insoluble extracellular fibrils.
  • This deposition impairs tissue structure and function, leading to various clinical manifestations.
  • Diseases are classified by the fibril precursor protein, with over 20 known types.

Purpose of the Study:

  • To provide a comprehensive overview of amyloidosis, encompassing its molecular basis, clinical aspects, and therapeutic advancements.
  • To highlight the common structural features of amyloid fibrils and the role of associated molecules.
  • To underscore the impact of increased understanding on disease management and future treatment strategies.

Main Methods:

  • Review of existing literature on protein misfolding and amyloid formation.

Related Experiment Videos

  • Analysis of the structural characteristics of amyloid fibrils and their constituents.
  • Synthesis of current knowledge regarding diagnosis, monitoring, and treatment of amyloidosis.

    • Main Results:

    • All amyloid fibrils share a common lamellar cross-beta-sheet structure.
    • Glycosaminoglycans and serum amyloid P component are universal non-fibrillar constituents.
    • Enhanced understanding of amyloidogenesis has improved diagnostic and therapeutic approaches.

    Conclusions:

    • Amyloidosis is a complex group of diseases with diverse etiologies but shared structural pathology.
    • Further research into amyloidogenesis promises novel therapeutic interventions.
    • Improved understanding facilitates better patient care through enhanced diagnosis and monitoring.